secwatch.observer — SEC 8-K summary
======================================

Issuer:     Sigyn Therapeutics, Inc. (SIGY)
CIK:        0001642159
Form:       8-K
Filed at:   2022-03-09T23:59:59+00:00
Accession:  0001493152-22-006402
Event type: leadership
Sentiment:  neutral
Materiality: 0.55
Item codes: 1.01, 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Sigyn Therapeutics appoints Jeremy Ferrell as CFO, effective March 9, 2022
--------------------------------------------------------------------------

- Jeremy Ferrell (CPA, MBA) appointed CFO; base salary $250,000/year, annual bonus up to 40%.
- Stock options for up to 600,000 shares at grant date market price; 25% vest at grant, rest over 3 years.
- Employment agreement is indefinite duration, at-will; includes standard terms.
- Ferrell has 25+ years finance experience; most recently CFO at Miku, Inc.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1642159/000149315222006402/0001493152-22-006402-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1642159/000149315222006402/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001493152-22-006402

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer